Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Multi-centre implementation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.

Created on 19 Nov 2026

Authors

Robert D Morgan, George J Burghel, Joseph M Shaw, Helene Schlecht, Bethany M Barnes, Sandy Chevrier, Romain Boidot, Marie-Pierre Wissler, Stéphanie Herveau, Apolline Thomas, Etienne Muller, Marie-Magdelaine Coude, Guillaume Herbreteau, Alexander Kurze, D Gareth R Evans, Gordon C Jayson, Andrew R Clamp, Stephen S Taylor

Published in

The Journal of molecular diagnostics : JMD. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Low-coverage whole-genome sequencing offers a scalable approach to homologous recombination deficiency (HRD) testing in ovarian cancer. This multi-centre study describes the real-world implementation of one such assay, SeqOne SomaHRD, across four European laboratories between 9 January 2023 and 1 October 2025. Tumours were classified as HRD-positive if they had a Genomic Instability score (GIS) of ≥0.50 (GIS-high) and/or a pathogenic BRCA1/2 variant. GIS was generated from two bioinformatically derived measures of genomic instability: Large-scale Genomic Alterations (LGA) and Loss of Parental Copy (LPC). A GIS was generated for 2,608/2,625 (99.4%) tumours: GIS-high in 765 (29.3%), GIS-low in 1,684 (64.6%), and GIS-inconclusive in 159 (6.1%). BRCA1/2 genotype was available for 1,226/2,625 (46.7%) tumours, of which 142 (11.6%) had a pathogenic BRCA1/2 variant. Of the 1,130 tumours with both a reportable GIS and known BRCA1/2 genotype, 413 (36.5%) had HRD-positive status, including 135 with a pathogenic BRCA1/2 variant and 278 (24.6%) with BRCA1/2 wild-type and GIS-high. Clinical turnaround time was ≤21 days for 2,573/2,625 (98.0%) tumours. Decentralised, low-coverage whole-genome sequencing generated a GIS for ovarian cancer within a consistently practical turnaround time and with a low rate of inconclusive results, identifying 278/1,130 (24.6%) evaluable tumours as HRD-positive based on genomic instability alone, without a pathogenic BRCA1/2 variant.

PMID:
43051585
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement